Javed Shamama, Alshehri Sultan, Shoaib Ambreen, Ahsan Waquar, Sultan Muhammad Hadi, Alqahtani Saad Saeed, Kazi Mohsin, Shakeel Faiyaz
Department of Pharmaceutics, College of Pharmacy, Jazan University, P.O. Box 114, Jazan 45142, Saudi Arabia.
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Pharmaceutics. 2021 Mar 10;13(3):368. doi: 10.3390/pharmaceutics13030368.
Recently, drug delivery using natural biological carriers has emerged as one of the most widely investigated topics of research. Erythrocytes, or red blood cells, can act as potential carriers for a wide variety of drugs, including anticancer, antibacterial, antiviral, and anti-inflammatory, along with various proteins, peptides, enzymes, and other macromolecules. The red blood cell-based nanocarrier systems, also called nanoerythrosomes, are nanovesicles poised with extraordinary features such as long blood circulation times, the ability to escape immune system, the ability to release the drug gradually, the protection of drugs from various endogenous factors, targeted and specified delivery of drugs, as well as possessing both therapeutic and diagnostic applications in various fields of biomedical sciences. Their journey over the last two decades is escalating with fast pace, ranging from in vivo to preclinical and clinical studies by encapsulating a number of drugs into these carriers. Being biomimetic nanoparticles, they have enhanced the stability profile of drugs and their excellent site-specific targeting ability makes them potential carrier systems in the diagnosis and therapy of wide variety of tumors including gliomas, lung cancers, breast cancers, colon cancers, gastric cancers, and other solid tumors. This review focuses on the most recent advancements in the field of nanoerythrosomes, as an excellent and promising nanoplatform for the novel drug delivery of various drugs particularly antineoplastic drugs along with their potential as a promising diagnostic tool for the identification of different tumors.
近年来，利用天然生物载体进行药物递送已成为研究最为广泛的课题之一。红细胞，即红血球，可作为多种药物的潜在载体，这些药物包括抗癌药、抗菌药、抗病毒药和抗炎药，以及各种蛋白质、肽、酶和其他大分子。基于红细胞的纳米载体系统，也称为纳米红细胞体，是具有非凡特性的纳米囊泡，如长血液循环时间、逃避免疫系统的能力、逐渐释放药物的能力、保护药物免受各种内源性因素影响、药物的靶向和特定递送，以及在生物医学科学的各个领域具有治疗和诊断应用。在过去二十年中，它们的发展步伐不断加快，通过将多种药物封装到这些载体中，从体内研究发展到临床前和临床研究。作为仿生纳米颗粒，它们提高了药物的稳定性，其出色的位点特异性靶向能力使其成为包括神经胶质瘤、肺癌、乳腺癌、结肠癌、胃癌和其他实体瘤在内的多种肿瘤诊断和治疗中的潜在载体系统。本综述重点关注纳米红细胞体领域的最新进展，它是一种出色且有前景的纳米平台，用于各种药物特别是抗肿瘤药物的新型药物递送，以及作为识别不同肿瘤的有前景的诊断工具的潜力。
